Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

NCT00001677 is registered in ClinicalTrials.gov with National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) as lead sponsor.

NCT NCT00001677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00001677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 1998
Completion date
April 30, 2000
Enrollment
40
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid, synovitis